Horizon Pharma Targets Actavis Over Generic Rayos

Law360, New York (August 28, 2013, 6:52 PM EDT) -- Swiss drugmakers Horizon Pharma AG and Jagotec AG hit Actavis Inc. with a suit in New Jersey federal court Monday, sayings its planned generic version of anti-inflammatory drug Rayos infringes several patents covering the drug and its dispenser.

According to Horizon, a planned generic version of delayed-release prednisone tablets by Actavis and Watson infringes five patents licensed by Horizon and Jagotec for Rayos — U.S. Patent Numbers 6,488,960; 6,677,326; 8,168,218; 8,309,124; and 8,394,407.

“Plaintiffs will be substantially and irreparably harmed if defendants are not enjoined from...
To view the full article, register now.